Loading...
•
Dec 31, 2021
Immunic Q4 2021 Earnings Report
Reported financial results for the fourth quarter and year ended December 31, 2021, and highlighted recent activity.
Key Takeaways
Immunic, Inc. reported its year-end 2021 financial results, highlighting clinical progress across key pipeline programs, including vidofludimus calcium (IMU-838) and IMU-935. Enrollment was initiated in the Phase 3 ENSURE program for relapsing multiple sclerosis, and positive results were reported from the Phase 1 clinical trial of IMU-935.
Initiated enrollment in Phase 3 ENSURE program of Vidofludimus Calcium for the treatment of relapsing multiple sclerosis.
Final Cohort 2 data from the Phase 2 EMPhASIS Trial confirms Phase 3 dose selection.
Completed enrollment of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in moderate-to-severe Ulcerative Colitis; top-line data expected in June of 2022.
Reported positive results from the single and multiple ascending dose parts of the Phase 1 clinical trial of IMU-935.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...